Table 3. Comparison of crossover treatment from bevacizumab to ranibizumab.
| Parameters | Before crossover bevacizumab (n=22) | After crossover ranibizumab (n=22) | P |
| Final logMAR (Snellen equivalent) | 0.52±0.09 (20/60) | 0.51=0.09 (20/60) | 0.91 |
| logMAR change | -0.24±0.07 | -0.02=0.07 | 10.04 |
| Equivalent lines/ETDRS letters gained | 2.4 lines/12 ETDRS letters | 0.2 lines/1 ETDRS letter | |
| Eyes gaining >3 lines | 9/22 (41%) | 4/22 (18%) | 0.10 |
| Eyes losing >3 lines | 2/22 (9%) | 2/22 (9%) | 1.00 |
| Central subfield (µm) change | -7±54 (n=17) | -72=49 (n=21) | 0.38 |
| Residual intraretinal fluid | 20/21 (95%) | 15/21 (71%) | 10.04 |
| Residual subretinal fluid | 7/21 (33%) | 9/21 (43%) | 0.53 |
| IOP (mmHg) change | 0.82=0.92 | -0.55=0.92 | 0.30 |
| Total injections | 5.7=0.84 | 6.5=0.84 | 0.52 |
| Days to final follow-up2 | 302.5=41.9 | 335.4=41.9 | 0.58 |
| Days between injections | 62.0=15.8 | 72.0=15.8 | 0.66 |
1Statistically significant; 2Prior to crossover, defined as the visit when a change in treatment was initiated; IOP: Intraocular pressure.